Kenvue Presents New Skin and Hair Research at EADV 2026
Key Takeaways
- Research presented by Kenvue brands at EADV 2026 includes studies of niacinamide- and trehalose-containing sunscreens, colloidal oat formulations, and 5% topical minoxidil for a range of skin and hair concerns.
- Neutrogena sunscreen studies reported changes in hydration, oiliness, redness, hyperpigmentation, and other visible skin measures, while Aveeno research evaluated colloidal oat formulations in UV-exposed skin and as adjunctive eczema care.
- A post hoc analysis of a Phase III trial of 5% minoxidil topical foam found greater numerical hair-count increases among younger men and those with earlier-stage androgenetic alopecia, although the subgroup findings should not establish that earlier treatment causes greater regrowth.
New research presented at the European Academy of Dermatology and Venereology (EADV) Congress 2026 examines topical formulations containing niacinamide, trehalose, colloidal oat, and minoxidil across several skin and hair concerns.
Kenvue announced 12 data sets involving its Neutrogena, Aveeno, and Regaine brands, including studies addressing oily and acne-prone skin, hyperpigmentation, dry skin, eczema, ultraviolet (UV)-related skin changes, and androgenetic alopecia.
Studies Examine Sunscreen, Colloidal Oat, and Minoxidil
Two studies evaluated Neutrogena sunscreens. In small Brazilian populations with oily, acne-prone skin, use of a broad-spectrum sunscreen containing 2% trehalose and 2% niacinamide was associated with a 56% reduction in visible redness, 46% reduction in acne-related hyperpigmentation, and up to 12% reduction in oiliness after 28 days. A separate study of a sunscreen containing 2% niacinamide and vitamins C and E reported a 22% improvement in hydration, maintenance of skin barrier integrity, and improvements in measures of skin tone and visible hyperpigmentation.
Aveeno research included preclinical and clinical studies evaluating colloidal oat-containing formulations following UV exposure. Reported findings included changes in skin barrier proteins, hydration, and ceramide production. Separately, an international survey of 178 dermatologists and pediatric clinicians found that 87.6% frequently recommended a specific colloidal oat-based emollient alongside topical corticosteroids for eczema, while 92.7% reported observing steroid-sparing or steroid-optimization effects.
A post hoc analysis of a Phase III trial evaluated 5% minoxidil topical foam in men with androgenetic alopecia. After 16 weeks, mean non-vellus hair-count increases were 26.25 among men aged 20 to 30 years versus 19.93 among those older than 30 years. Mean increases were 23.06 among men with Norwood-Hamilton Type III hair loss versus 18.70 among those with Type IV or V disease. Improvements versus placebo were reported across hair-loss classifications (P < .002).